These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 2237777

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain.
    Lappalainen J, Hietala J, Koulu M, Seppälä T, Sjöholm B, Syvälahti E.
    J Pharmacol Exp Ther; 1990 Feb; 252(2):845-52. PubMed ID: 2179533
    [Abstract] [Full Text] [Related]

  • 6. Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment.
    Zhang Y, Xu H, He J, Yan B, Jiang W, Li X, Li XM.
    Neurosci Lett; 2007 Jun 08; 420(1):66-71. PubMed ID: 17466452
    [Abstract] [Full Text] [Related]

  • 7. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies.
    Huang N, Ase AR, Hébert C, van Gelder NM, Reader TA.
    Neurochem Int; 1997 Mar 08; 30(3):277-90. PubMed ID: 9041559
    [Abstract] [Full Text] [Related]

  • 8. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
    Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A.
    J Pharmacol Exp Ther; 1999 Mar 08; 288(3):1002-14. PubMed ID: 10027837
    [Abstract] [Full Text] [Related]

  • 9. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 08; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 10. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain.
    Wilmot CA, Szczepanik AM.
    Brain Res; 1989 May 22; 487(2):288-98. PubMed ID: 2525063
    [Abstract] [Full Text] [Related]

  • 11. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, Haleem MA.
    Med Sci Monit; 2002 Sep 22; 8(9):BR354-61. PubMed ID: 12218936
    [Abstract] [Full Text] [Related]

  • 12. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens.
    Compton DR, Johnson KM.
    J Pharmacol Exp Ther; 1989 Feb 22; 248(2):521-30. PubMed ID: 2918468
    [Abstract] [Full Text] [Related]

  • 13. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
    Saller CF, Czupryna MJ, Salama AI.
    J Pharmacol Exp Ther; 1990 Jun 22; 253(3):1162-70. PubMed ID: 2141636
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats.
    Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM.
    Synapse; 1999 Dec 15; 34(4):266-76. PubMed ID: 10529721
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
    Gygi SP, Gibb JW, Hanson GR.
    J Pharmacol Exp Ther; 1994 Jul 15; 270(1):192-7. PubMed ID: 7913495
    [Abstract] [Full Text] [Related]

  • 16. Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol.
    Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J.
    J Pharmacol Exp Ther; 1993 Mar 15; 264(3):1262-7. PubMed ID: 8383744
    [Abstract] [Full Text] [Related]

  • 17. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
    Boyson SJ, McGonigle P, Luthin GR, Wolfe BB, Molinoff PB.
    J Pharmacol Exp Ther; 1988 Mar 15; 244(3):987-93. PubMed ID: 2908050
    [Abstract] [Full Text] [Related]

  • 18. The importance of serotonin-dopamine interactions in the action of clozapine.
    Meltzer HY.
    Br J Psychiatry Suppl; 1992 May 15; (17):22-9. PubMed ID: 1358125
    [Abstract] [Full Text] [Related]

  • 19. Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs.
    Atkins JB, Chlan-Fourney J, Nye HE, Hiroi N, Carlezon WA, Nestler EJ.
    Synapse; 1999 Aug 15; 33(2):118-28. PubMed ID: 10400890
    [Abstract] [Full Text] [Related]

  • 20. Serotonergic involvement in haloperidol-induced catalepsy.
    Neal-Beliveau BS, Joyce JN, Lucki I.
    J Pharmacol Exp Ther; 1993 Apr 15; 265(1):207-17. PubMed ID: 8386235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.